Abstract 134P
Background
An important proportion of patients receiving PARPi will become resistant. Doxorubicin is one of the drugs used as standard of care in HGSOC becoming resistant to platinum. The ROLANDO trial showed an encouraging activiy in platinum-resistant HGSOC of the combinacion of OLA-Doxo. The aim of our study was to assess if doxorubicin and OLA are synergistic in both PARP-I sensibitve and PARPi- resistant models.
Methods
8 cell lines, 4 parental and 4 corresponding OLA resistant clonal lines were used. One triple-negative breast cancer (TNBC) line (MDA-MB-231) and 3 HGSOC OLA-sensitive cell lines (PEO1, Kuramochi and SKOV3) were acquired. We generated 4 OLA resistant cell lines (MDA-MB-231-R, Kuramochi-R, PEO1-R and SKOV3-R) by exposure to OLA. IC50 of OLA and doxorubicin and the combination of both (combo) were calculated in all 8 lines (sensitive and resistance). Synergism between both drugs was assessed with the Chou Talalay method for combination index (CI) at Fa50. BRCA status (mutation vs wild type (wt)) was assessed by NGS in every line.
Results
When compared with parental lines DOXO IC50 was statistically superior in resistant cell lines except in PEO1-R suggesting a potential cross-resistant between OLA and DOXO. DOXO + OLA were synergistic in both parental and OLA-resistant lines in MDA-MB-231, PEO1 and SKOV3, with Fa50 for resistant lines=0.41 and 0.38 and 0.67 respectively. However, in Kuramochi combo was not synergistic, with Fa 50=1.36. DNA damage assessed by H2AX was similar between combo and DOXO single agent in all parental and resistant lines. Table: 134P
MD231 | MD231R | PEO1 | PEO1R | Kura | KuraR | SKOV3 | SKOV3R | |
BRCA mutation | Wt | Wt | BRCA2 | BRCA2 | BRCA2 | BRCA2 | Wt | Wt |
DOXO IC50 (nM) | 313.3 | 676.2 | 101.2 | 67.3 | 122.6 | 995.3 | 312.1 | 581.5 |
Chou Talalay (Fa 50) | 0.5 | 0.41 | 0.44 | 0.38 | 1.36 | 0.97 | 0.25 | 0.67 |
Conclusions
Our in vitro models suggest that OLA-resistant cells have a cross-resistance to Doxo. However synergistic effect of OLA+DOXO is observed in most OLA-resistant cell lines except in kuramochi-R. Further analyses will confirm whether this combination might be a valuable strategy to overcome OLA-resistance.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
INCLIVA.
Funding
AstraZeneca.
Disclosure
J.A. Perez Fidalgo: Financial Interests, Personal, Invited Speaker: AstraZeneca, Clovis, GSK, PharmaMar, AstraZeneca, Artios Pharma; Financial Interests, Personal, Advisory Board: AstraZeneca, GSK, Clovis, PharmaMar, Roche, Abilify Pharma; Financial Interests, Personal, Full or part-time Employment, Associate Professor: University of Valencia; Financial Interests, Institutional, Research Grant: GSK, PharmaMar; Financial Interests, Institutional, Invited Speaker: Novartis, AstraZeneca; Financial Interests, Institutional, Funding: GSK; Non-Financial Interests, Personal, Project Lead, Coordinating PI Phase III trial in breast cancer: Novartis; Non-Financial Interests, Personal, Member, Member of the Early Drug Development working group: ENGOT; Non-Financial Interests, Personal, Leadership Role, Member of the Executive Committee and Head of the Scientific Committee: GEICO; Non-Financial Interests, Personal, Leadership Role, Member of the Executive Committee and co-coordinator of Uterine Sarcoma Group: GEIS; Non-Financial Interests, Personal, Leadership Role, Co-chair Phase 2 group: GCIG; Non-Financial Interests, Personal, Member: BIG; Non-Financial Interests, Personal, Member, Adolescent and Young Adults working group: SEOM.M. Mendiola: Financial Interests, Personal, Speaker’s Bureau: AstraZeneca, MSD; Financial Interests, Personal, Invited Speaker: GSK; Financial Interests, Institutional, Research Grant: Eisai; Financial Interests, Personal, Research Grant: PharmaMar; Financial Interests, Personal, Other: Roche, Pfizer. A. Redondo Sanchez: Financial Interests, Personal, Invited Speaker: MSD, AstraZeneca, GSK, Clovis, PharmaMar; Financial Interests, Personal, Advisory Board: MSD, AstraZeneca, GSK, Clovis, PharmaMar; Financial Interests, Institutional, Invited Speaker: Roche, Eisai, PharmaMar. B. Pineda Merlo: Financial Interests, Institutional, Research Grant: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
10P - An adapted CGP-based model to interpret POLE mutations in endometrial cancer
Presenter: Rita Trozzi
Session: Cocktail & Poster Display session
Resources:
Abstract
11P - Reconstructing tumour evolution of single cells using both somatic mutations and copy-number alterations
Presenter: Rija Zaidi
Session: Cocktail & Poster Display session
Resources:
Abstract
12P - Swiss-PO: Molecular modelling for precision oncology
Presenter: Fanny Krebs
Session: Cocktail & Poster Display session
Resources:
Abstract
13P - A novel algorithm for predicting variant detectability in oncogenomic analysis
Presenter: Alper Akkuş
Session: Cocktail & Poster Display session
Resources:
Abstract
14P - expHRD: An algorithm for the transcriptome-based estimation of homologous recombination deficiency score
Presenter: Jin-Ku Lee
Session: Cocktail & Poster Display session
Resources:
Abstract
15P - ClinBioNGS: An integrated clinical bioinformatics pipeline for the analysis of somatic NGS cancer panels
Presenter: Xavier Sole
Session: Cocktail & Poster Display session
Resources:
Abstract
16P - Investigation of c-MYC role in DNA-PK-mediated activation of STING pathway in SCLC
Presenter: Caterina de Rosa
Session: Cocktail & Poster Display session
Resources:
Abstract
17P - NRF2 activation promotes HER2-targeted tolerance and resistance in oesophageal adenocarcinoma through metabolic reprogramming to glutathione
Presenter: Wei Zhang
Session: Cocktail & Poster Display session
Resources:
Abstract
18P - AURKB inhibition radiosensitises NSCLC by altering mitotic fate
Presenter: Kathryn Egerton
Session: Cocktail & Poster Display session
Resources:
Abstract
19P - Stratified control study on neuroendocrine differentiation and potential clinical markers in patients with limited-stage small-cell lung cancer
Presenter: Li Liu
Session: Cocktail & Poster Display session
Resources:
Abstract